Douglas Flora: Afreen Shariff is joining the editorial board of AI in Precision Oncology

Douglas Flora shared a post on LinkedIn by Afreen Shariff, adding:

“Exciting News!

I am thrilled to announce that Afreen Shariff, MD of the Duke Cancer Institute, is joining the editorial board of AI in Precision Oncology. Dr. Shariff is a national leader in the intersection of endocrinology and oncology, pioneering advancements in managing cancer therapy-related endocrine disorders.

As the Director of the Duke Endo-Oncology Program, Associate Director for the Cancer Therapy Toxicity Program at the Duke Center for Cancer Immunotherapy, and Chair of the Oncoendocrinology Special Interest Group with the Endocrine Society, she’s pushing the boundaries of how we integrate AI into clinical practice for improved patient outcomes.

Perfect timing: she was just interviewed for the Target Cancer podcast by another AIPO editor, Sanjay Juneja, M.D. These are two people who will be found. I’m so glad you two connected.

Both are inspiring leaders in Oncology, driving the crucial changes we need. I’m excited to tune in for the entire podcast episode. If you aren’t already following these guys, now’s the time—they deliver outstanding content!”

Quoting Afreen Shariff’s post:

“Official PODpic!

Loved having this information dense, high energy and most importantly-enjoyable conversation with Sanjay Juneja, M.D. from Target Cancer Podcast. We connected on all things side effects and how Citrus Oncology is the answer to improving insight, access and care for one of the most deserving patients- Our Cancer warriors!

Stay tuned for the episode.”

Source: Douglas Flora/LinkedIn and Afreen Shariff/LinkedIn

More posts featuring Douglas Flora and Afreen Shariff in OncoDaily.

Douglas Flora is the Executive Medical Director of Oncology Services at St. Elizabeth Healthcare, overseeing clinical operations, strategic planning, and the expansion of cancer programs. He is also the co-founder of the Center for Precision Medicine; Genomic Health.

As the Editor-in-Chief of ‘AI in Precision Oncology,’ he plays a pivotal role in advancing research. He is also an active board member of the American Cancer Society and ACCC, where he contributes to advocacy, education, and innovation within the cancer community.

Afreen Shariff is an endocrinologist specializing in endocrine diseases affecting cancer patients. She directs the Duke Endo-Oncology Program and serves as Associate Director for the Cancer Therapy Toxicity Program at the Duke Center for Cancer Immunotherapy.

Dr. Shariff is also an Associate Professor of Medicine in the Division of Endocrinology, Diabetes, and Metabolism at Duke University School of Medicine. Additionally, she is a Board Member of the Association of Cancer Care Centers and a Co-Founder of Citrus Oncology.